Next Article in Journal
Multifunctional Composites of Chiral Valine Derivative Schiff Base Cu(II) Complexes and TiO2
Previous Article in Journal
Valproic Acid as a Potential Inhibitor of Plasmodium falciparum Histone Deacetylase 1 (PfHDAC1): An in Silico Approach
Previous Article in Special Issue
Rescue Effects: Irradiated Cells Helped by Unirradiated Bystander Cells
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(2), 3932-3954;

Tumor Immunotargeting Using Innovative Radionuclides

Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France
Department of Nuclear Medicine, University Hospital, Nantes 44093, France
Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-Site Gauducheau, Saint-Herblain 44805, France
Department of Radiology, University Hospital, Nantes 44093, France
AMAROC, ONIRIS, Nantes 44300, France
Physics Department, Groupement d'Intérêt Public Arronax, Nantes 44817, France
Author to whom correspondence should be addressed.
Academic Editor: Sophie E. Eriksson
Received: 5 January 2015 / Accepted: 29 January 2015 / Published: 11 February 2015
(This article belongs to the Special Issue Frontiers of Radioimmunotherapy)
Full-Text   |   PDF [829 KB, uploaded 11 February 2015]   |  


This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality. View Full-Text
Keywords: innovative radionuclides; alpha particle-emitting radionuclides; alpha-immunotherapy; radioimmunotherapy; immuno-PET innovative radionuclides; alpha particle-emitting radionuclides; alpha-immunotherapy; radioimmunotherapy; immuno-PET

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kraeber-Bodéré, F.; Rousseau, C.; Bodet-Milin, C.; Mathieu, C.; Guérard, F.; Frampas, E.; Carlier, T.; Chouin, N.; Haddad, F.; Chatal, J.-F.; Faivre-Chauvet, A.; Chérel, M.; Barbet, J. Tumor Immunotargeting Using Innovative Radionuclides. Int. J. Mol. Sci. 2015, 16, 3932-3954.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top